EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative analysis of adjuvant therapy for stage III BRAF ‐mut melanoma: A real‐world retrospective study from single center in China

Jingqin Zhong iD, Wei Sun iD, Tu Hu, Chunmeng Wang, Wangjun Yan, Zhiguo Luo, Xin Liu, Yu Xu, Yong Chen iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jingqin Zhong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BRAF V600 mutation is the most common oncogenic alternation in melanoma and is visible in around 50% of cutaneous and 10%–15% of acral or mucosal subtypes. Currently, immunotherapy with anti‐PD‐1 blockade and dual‐targeted therapy with Dabrafenib plus trametinib (D + T) target therapy have been approved as adjuvant therapies for Stage III melanoma with BRAF V600 mutation. According to their phase III clinical trials, 3‐year recurrence‐free survival (RFS) is around 60% for both types of treatment. However, early disease control was slightly more effective with targeted therapy than immunotherapy. With different drug approval deadlines in China, anti‐PD1 monotherapy, D + T combination, and Vemurafenib (V) monotherapy have all been used in real clinical practice as adjuvant settings for stage III BRAF‐mut melanoma in recent years. We conducted this retrospective study to evaluate the efficacy of different treatments in the Chinese melanoma population.

Methods

Patients who underwent radical surgery and were diagnosed as Stage III melanoma harboring BRAF V600 mutation by pathological report were retrospectively identified at Fudan University Shanghai Cancer Center from January 2017 to December 2021. Patients with mucosal melanoma, or with follow‐up of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsMelanomaHumansRetrospective StudiesProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsChinaAdjuvants, ImmunologicMutationPyridonesPyrimidinonesCutaneous Malignant Melanoma

Stichwörter der Autor:innen

BRAF mutationDabrafenibPD-1 inhibitorTrametinibVemurafenibadjuvant therapymelanoma

Substanzen

Proto-Oncogene Proteins B-rafAdjuvants, ImmunologicPyridonesPyrimidinonesBRAF protein, human

Autor:innen und Institutionen

  • Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Jingqin Zhong, Wei Sun, Yong Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhong, J., Sun, W., Hu, T., Wang, C., Yan, W., Luo, Z., Liu, X., Xu, Y., & Chen, Y. (2023). Comparative analysis of adjuvant therapy for stage III BRAF ‐mut melanoma: A real‐world retrospective study from single center in China. Cancer Medicine. https://doi.org/10.1002/cam4.5866

Vancouver

Zhong J, Sun W, Hu T, Wang C, Yan W, Luo Z, et al. Comparative analysis of adjuvant therapy for stage III BRAF ‐mut melanoma: A real‐world retrospective study from single center in China. Cancer Medicine. 2023. doi:10.1002/cam4.5866

BibTeX
@article{Zhong2023,
  author = {Zhong, Jingqin and Sun, Wei and Hu, Tu and Wang, Chunmeng and Yan, Wangjun and Luo, Zhiguo and Liu, Xin and Xu, Yu and Chen, Yong},
  title = {Comparative analysis of adjuvant therapy for stage III BRAF ‐mut melanoma: A real‐world retrospective study from single center in China},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5866}
}
Kostenlos starten →